Back to Search
Start Over
Survival of patients with clinical stage IIIA non-small cell lung cancer after induction therapy: age, mediastinal downstaging, and extent of pulmonary resection as independent predictors.
- Source :
-
The Journal of thoracic and cardiovascular surgery [J Thorac Cardiovasc Surg] 2011 Jan; Vol. 141 (1), pp. 48-58. Date of Electronic Publication: 2010 Nov 18. - Publication Year :
- 2011
-
Abstract
- Background: In clinical stage IIIA non-small cell lung cancer, the role of surgical resection, particularly pneumonectomy, after induction therapy remains controversial. Our objective was to determine factors predictive of survival after postinduction surgical resection.<br />Methods: We retrospectively reviewed a prospectively collected database of 136 patients who underwent surgical resection after induction chemotherapy (n = 119) or chemoradiation (n = 17) from June 1990 to January 2010.<br />Results: One hundred five lobectomies or bilobectomies and 31 pneumonectomies were performed. There was 1 perioperative death (pneumonectomy). Seventy-one patients had downstaging to N0 or N1 nodal status (52%). There were 2 complete pathologic responses. Median follow-up was 42 months (range, 0.69-136 months). Overall 5-year survival for entire cohort was 33% (36% lobectomy, 22% pneumonectomy, P = .001). Patients with pathologic downstaging to pN0 or pN1 had improved 5-year survival (45% vs 20%, P = .003). For patients with pN0 or pN1 disease, survival after lobectomy was better than after pneumonectomy (48% vs 27%, P = .011). In patients with residual N2 disease, there was no statistically significant survival difference between lobectomy and pneumonectomy (5-year survival, 21% vs 19%; P = .136). Multivariate analysis showed as independent predictors of survival age (hazard ratio, 1.05; P = .002), extent of resection (hazard ratio, 2.01; P = .026), and presence of residual pN2 (hazard ratio, 1.60; P = .047).<br />Conclusions: After induction therapy for patients with clinical stage IIIA disease, both pneumonectomy and lobectomy can be safely performed. Although survival after lobectomy is better, long-term survival can be accomplished after pneumonectomy for appropriately selected patients. Nodal downstaging is important determinant of survival, particularly after lobectomy.<br /> (Copyright © 2011 The American Association for Thoracic Surgery. Published by Mosby, Inc. All rights reserved.)
- Subjects :
- Adult
Age Factors
Aged
Aged, 80 and over
Carcinoma, Non-Small-Cell Lung mortality
Carcinoma, Non-Small-Cell Lung pathology
Chemotherapy, Adjuvant
Chi-Square Distribution
Disease-Free Survival
Female
Hospital Mortality
Humans
Kaplan-Meier Estimate
Lung Neoplasms mortality
Lung Neoplasms pathology
Lymph Nodes pathology
Male
Mediastinoscopy
Middle Aged
Neoadjuvant Therapy
Neoplasm Staging
Proportional Hazards Models
Radiotherapy, Adjuvant
Retrospective Studies
Risk Assessment
Risk Factors
Survival Rate
Time Factors
Treatment Outcome
Carcinoma, Non-Small-Cell Lung therapy
Lung Neoplasms therapy
Pneumonectomy adverse effects
Pneumonectomy mortality
Subjects
Details
- Language :
- English
- ISSN :
- 1097-685X
- Volume :
- 141
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- The Journal of thoracic and cardiovascular surgery
- Publication Type :
- Academic Journal
- Accession number :
- 21092990
- Full Text :
- https://doi.org/10.1016/j.jtcvs.2010.07.092